Telix Pharmaceuticals Limited cash flow to debt ratio of -3.71% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Telix Pharmaceuticals Limited's free cash flow has decreased -388.42% from $28.71M last year to $-82.80M, signaling decreasing performance

Telix Pharmaceuticals Limited's debt to equity ratio is 1.12, which means that the company's assets are unhealthy financed, signaling financial risk. READ MORE: A ratio over 0.60 means the company finances its assets with debt, signaling financial risk. If ratio is negative, the company spent its own equity and risks bankruptcy

Telix Pharmaceuticals Limited's debt has increased relative to shareholder equity from 1.02 last year to 1.12 today, signaling weakened financials

Telix Pharmaceuticals Limited has a net debt to EBITDA ratio of 6.10x, which exceeds the 3.00x threshold, indicating high leverage and potential financial risk

Telix Pharmaceuticals Limited's interest coverage ratio is 0.45, which means that the company struggles to meet interest obligations, signaling financial risk.

Telix Pharmaceuticals Limited's profit margin has decreased (-113.92%) in the last year from 6.37% to -0.89%, signaling decreasing performance

Telix Pharmaceuticals Limited's short-term assets of $494.79M exceed its short-term liabilities of $347.00M

Telix Pharmaceuticals Limited's return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Telix Pharmaceuticals Limited's return on equity of -1.72%, is lower than 15.00%, indicating bad performance

Telix Pharmaceuticals Limited's operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Telix Pharmaceuticals Limited had positive net income in only 2.00 out of 5 years, indicating unstable earnings

Telix Pharmaceuticals Limited has negative free cash flow, indicating the company is burning cash rather than generating it

Telix Pharmaceuticals Limited has negative free cash flow, indicating cash burn

Telix Pharmaceuticals Limited's yearly earnings has decreased -121.40% since last year from $49.92M to $-10.69M, signaling decreasing performance

Telix Pharmaceuticals Limited's yearly revenue has increased 53.91% since last year from $783.21M to $1.21G, signaling increasing performance

ROIC 1.77% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Telix Pharmaceuticals Limited's 3-year revenue CAGR of 96.00% is positive, indicating growing revenue over the past 3 years

Telix Pharmaceuticals Limited had revenue growth in 5.00 out of 5 years, indicating consistent revenue performance

Telix Pharmaceuticals Limited had positive ROE in only 2.00 out of 5 years, indicating inconsistent returns on equity

Telix Pharmaceuticals Limited has insufficient data to evaluate this check.

Telix Pharmaceuticals Limited has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Telix Pharmaceuticals Limited is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Telix Pharmaceuticals Limited has an EV/EBITDA ratio of 52.87x, which exceeds the 20.00x threshold, indicating the stock may be overvalued relative to its operating earnings

Telix Pharmaceuticals Limited is overvalued relative to its fair value price of 1.79 based on Earnings Fair Value model

Telix Pharmaceuticals Limited has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Telix Pharmaceuticals Limited has a price-to-book ratio of 5.99x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Telix Pharmaceuticals Limited has a price-to-sales ratio of 3.05x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue